PubRank

Markus Warmuth

Author PubWeight™ 83.21‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012 31.78
2 Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet 2004 3.96
3 Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK. Proc Natl Acad Sci U S A 2006 3.83
4 Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 2010 3.39
5 Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013 3.27
6 Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008 3.01
7 Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010 2.86
8 Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007 2.62
9 An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci U S A 2006 2.51
10 A general strategy for creating "inactive-conformation" abl inhibitors. Chem Biol 2006 2.27
11 Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med 2010 1.77
12 B-Raf kinase inhibitors for cancer treatment. Curr Opin Investig Drugs 2007 1.67
13 Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature 2016 1.52
14 Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011 1.30
15 Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling. Proc Natl Acad Sci U S A 2011 1.29
16 Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett 2008 1.17
17 Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site. Biochim Biophys Acta 2010 1.16
18 The Polycomb group protein Bmi-1 is essential for the growth of multiple myeloma cells. Cancer Res 2010 1.09
19 The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. Cancer Res 2010 1.01
20 A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl. J Med Chem 2010 0.96
21 A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Mol Cell 2009 0.96
22 The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate. Blood 2002 0.93
23 Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL. Blood 2011 0.92
24 NAMPT is the cellular target of STF-31-like small-molecule probes. ACS Chem Biol 2014 0.90
25 Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells. Ann Hematol 2007 0.88
26 Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle 2010 0.88
27 Allosteric inhibition of BCR-ABL. Cell Cycle 2010 0.85
28 Src family tyrosine kinases phosphorylate Flt3 on juxtamembrane tyrosines and interfere with receptor maturation in a kinase-dependent manner. Ann Hematol 2007 0.79
29 Total synthesis of 6-deoxypladienolide D and Assessment of Splicing Inhibitory Activity in a Mutant SF3B1 cancer cell line. Org Lett 2014 0.78
30 Measuring the tyrosine kinase activity: a review of biochemical and cellular assay technologies. Expert Opin Drug Discov 2008 0.76